$MDT

Medtronic stock price target kept at $110 by TD Cowen on growth outlook

TD Cowen reiterated a Buy rating and $110 price target for Medtronic (MDT), citing growth momentum and undervaluation. The company reported strong Q1 FY2027 results, with 7% organic sales growth and 15.1% EPS increase. Bernstein raised its target to $105, while Needham set a $114 target. Medtronic also announced a $700M partnership and a MiniMed share exchange offer.

Original reporting
Published Sep 30, 2026, 1:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 3:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MDT
Bullish
high confidence
Mentioned
$MDT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

The combined analyst upgrades and strategic moves provide a fresh catalyst that could drive the stock higher in the short term.

02

Market read

New analyst target and partnership create actionable upside potential for MDT.

03

What to watch

Potential regulatory scrutiny of the robotics system and integration risks with MiniMed.

Relevance 7/10Novelty 6/10Timing: today

Background

Medtronic reported strong Q1 fiscal 2027 results and received multiple analyst upgrades, while also launching a strategic partnership and an exchange offer.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

TD Cowen reiterated a Buy rating on Medtronic, kept its price target at $110 and highlighted a new $700 million partnership with Cornerstone Robotics and an exchange offer for MiniMed shares.

Expected impact

likely upward pressure as investors price in the higher target and partnership benefits

Evidence & confidence

The price target increase to $110 from current $86.56 represents ~27% upside; the $700 M robotics deal and exchange offer provide concrete growth catalysts.

Market effects

Medical device sector may see renewed interest as Medtronic's electrophysiology and robotics initiatives gain traction.

U.S. healthcare stocks could benefit from the positive analyst coverage.

Limited to Medtronic and its partners; no broad macro effect.

Counterpoint

The partnership may not translate into near‑term revenue, and the exchange offer could dilute existing shareholders.

Key entities

  • Medtronic

    Medical device manufacturer (NYSE:MDT).

  • TD Cowen

    Equity research firm that reaffirmed a Buy rating and $110 price target.

  • Cornerstone Robotics

    Partner in a $700 million robotics distribution agreement.

Related articles

$MDTMedAI 8/10

Late-Breaking Clinical Trial Results Announced at The VEINS 2026

The VIVA Foundation presented late-breaking clinical trial results at The VEINS 2026 conference. Key findings include 88.1% ulcer healing rate with Cyanoacrylate Closure (CAC) for C6 disease, 100% technical success for the VEnice device in treating venous incompetence, and favorable 30-day results for the Abre Venous Stent System. The RAPID-PE study showed promising interim results for on-the-table mechanically channeled thrombolysis in acute intermediate-risk pulmonary embolism.

$MDTMedAI 8/10

Medtronic VenaSeal study shows 88.1% ulcer healing

Medtronic reported an 88.1% ulcer-healing rate over two years for its VenaSeal device, with 96% U.S. insurance coverage. The study involved 125 patients, showing a median healing time of 92 days and 77.1% recurrence-free rate. Medtronic shares closed at $86.38 on Friday, with market reaction pending.

$MDTHigh

Medtronic receives Category I CPT code approvals for two devices

Medtronic (MDT) received Category I CPT code approvals for its Altaviva and Symplicity Spyral devices, effective January 2028. These codes, assigned by the AMA, indicate established procedures with clinical evidence. The Altaviva device treats urinary incontinence, while the Symplicity Spyral system addresses high blood pressure. According to the company, the approvals reflect clinical evidence and physician adoption.

$MDTLow

Medtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems

Medtronic (MDT) received Category I CPT® codes for Altaviva™ and Symplicity Spyral™ systems, effective January 2028. These codes, replacing existing Category III codes, are permanent and indicate well-established procedures with robust clinical evidence. The Altaviva™ device treats urge urinary incontinence, while the Symplicity Spyral™ system addresses uncontrolled hypertension.